Transgene: Phase II Study With TG4001 Fails To Meet Primary Objective - Quick Facts

(RTTNews) - Transgene announced that its randomized Phase II study to evaluate TG4001 in combination with avelumab versus avelumab alone in patients with recurrent or metastatic HPV16-positive cervical and anogenital tumors has not met the primary objective of the study. The company noted that pre-planned subgroup analysis showed a positive efficacy trend in favor of the TG4001 containing regimen in cervical cancer patients, which requires further confirmation through additional analyses, including by PD-L1 status.

The company said it is evaluating the full study results in detail to determine the best way forward for this program and will communicate further once this is completed.

For More Such Health News, visit rttnews.com.